Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07027033
Recruiting Not applicable

Nutritional Oleic Acid Modulation of adIpose Cholesterol Metabolism in Patients Living With Obesity

NCT07027033 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-07-15
Last updated
2026-01-15

Condition(s) studied

ObesityVisceral Adipose TissueWhite Adipose Tissue InflammationSubcutaneous Adipose Tissue

Investigational drug(s) / intervention(s)

acid-rich sunflower oil oleic acidconventional sunflower oil

acid-rich sunflower oil oleic acid: Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid

conventional sunflower oil: Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil

Study summary

Disruption of white adipose tissue (WAT) homeostasis during obesity is central to the development of associated cardiometabolic complications. Dietary supplementation with oleic acid in obese patients can limit these complications. Experimental data, obtained in preclinical models, suggest that the beneficial effects of oleic acid may protect the TAB by increasing cholesterol esterification. The NAMICO study aims to test this hypothesis using TAB biopsies collected from obese patients undergoing bariatric surgery who had previously undergone dietary enrichment with either a conventional oil or an oil rich in oleic acid.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * • Individual who has given informed consent. * Female adult aged between 18 and 60 years (included). * Patient with obesity at inclusion, meeting the HAS criteria for bariatric surgery eligibility: BMI ≥ 35 kg/m² associated with a comorbidity or BMI \> 40 kg/m². * European origin: For this pilot study, we need to reduce variability factors and focus the research on women of European descent only (having both parents identified by the patient as of European origin). * Effective contraception if sexually active, or abstinence, or menopause (criterion required for bariatric surgery). * Presenting at inclusion with at least two clinical criteria of insulin resistance according to the definition of the International Diabetes Federation (IDF): * Dysglycemia (fasting glucose ≥ 100 mg/dL, glucose intolerance, or type 2 diabetes). * Hypertension (≥ 130/85 mm Hg). * Low HDL-cholesterol (\< 50 mg/dL). * Elevated triglycerides (≥ 150 mg/dL). * Affiliated with a social security system or a beneficiary of such a system. * Bariatric surgery performed at Nantes University Hospital (CHU de Nantes). Exclusion Criteria: * • Modification of diabetes treatment within the past month. * Ongoing or planned insulin therapy before bariatric surgery. * Modification of lipid-lowering treatment within the past three months. * Systemic corticosteroid therapy. * Antiviral therapy (HIV). * Dietary supplementation affecting lipid metabolism, including proactive margarine, Danacol, polyunsaturated fatty acid supplementation, or any other substance identified by the investigator. * Exocrine pancreatic insufficiency. * Pregnancy or breastfeeding. * History of organ transplantation. * Individual deprived of liberty or under legal protection (guardianship or trusteeship). * Any clinical condition in which the investigator considers that inclusion in the study may harm the patient's health or compromise the proper conduct of the study. * Participation in other clinical trials, except for non-interventional studies and research on surgical techniques or postoperative strategies. * Type I, monogenic or secondary diabetes.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU de Nantes Nantes France Recruiting

More Nantes University Hospital trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07027033 on ClinicalTrials.gov ↗ ← All trials in France